Development of magnetic resonance fingerprinting (MRF) to assess response to neoadjuvant chemotherapy in breast cancer
Active Project Grant Awarded Last action
- Award ID
- R01CA282516
- Recipient
-
Case Western Reserve University UEI HJMKEF7EJW69
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,387,393
Award facts
- Assistance listing
- 93.394 Cancer Detection and Diagnosis Research
- Completion date 64% complete
- Place of performance
- Cleveland, OH 44106, USA
Award details come from USAspending.gov.
Description
- Abstract
- In women, breast cancer is the most commonly diagnosed cancer and leading cause of cancer related deaths worldwide, with approximately 2.3 million new cases and 685,000 deaths in 2020. Neoadjuvant chemotherapy (NAC) is commonly applied to reduce the tumor size before surgery for breast neoplasms. Unfortunately, due to the genetic and phenotypic heterogeneity of breast tumors, not all patients respond to conventional NAC. Currently, only about 22% of patients show pathologic complete response (PCR), while the remaining non-PCR patients show either partial response (54% of all patients) or no response to chemotherapy. Early prediction of tumor response to chemotherapy to identify non-responders could 1) reduce unnecessary side effects and costs related to ineffective therapy, and 2) help physicians tailor the treatment plan earlier to achieve better therapeutic outcomes and improve survival. Monitoring tumor response to chemotherapy is currently based on tumor size measured by physical exam, which is subjective, difficult to quantify, and most importantly, temporally delayed compared to underlying biological changes. Quantitative, repeatable and objective methods that could provide an early detection of tumor physiological changes before size changes could significantly improve treatment outcome and the quality of patient care. However, quantitative imaging poses significant technical challenges, which is rarely performed in the clinical setting. Here, we propose to leverage magnetic resonance fingerprinting (MRF), a revolutionary new platform for quantitative MR that was invented by our team, to develop new imaging biomarkers for early assessment of treatment response in women with breast cancer. Our team has developed a breast MRF method to simultaneously generate quantitative 3D T1 and T2 maps in ~6 minutes with excellent reproducibility. We have also expanded our MRF method to simultaneous quantify T1, T2 and ADC maps of the brain with no image distortion. Here, we plan on optimizing this new relaxometry / diffusion MRF method specifically for women with breast cancer (aim 1). Novel deep learning methods will be developed to provide a fast (
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $634,858 | |
| Amendment | $651,638 | |
| Amendment | $536,972 | |
| Original award | $563,925 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Duke University | $198,340 | |
| Duke University | $206,390 |
Quick answers
Who received award R01CA282516?
R01CA282516 was awarded to Case Western Reserve University by National Cancer Institute (National Institutes of Health) on September 1, 2023.
How much is award R01CA282516 worth?
$2,387,393 has been obligated on R01CA282516.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award